Clinical Trial: Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma

U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07070700) titled 'Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic Cholangiocarcinoma' on July 09.

Brief Summary: This study will evaluate the efficacy and safety of cryoablation combined with lenvatinib plus QL1706 (iparomlimab/tuvonralimab) in patients with advanced Intrahepatic Cholangiocarcinoma (ICC) who have progressed after first-line treatment.

Study Start Date: Aug. 01

Study Type: INTERVENTIONAL

Condition: Intrahepatic Cholangiocarcinoma (Icc)

Intervention: DRUG: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

QL1706 will be administered by IV, 5 mg/kg on day 1 ...